Quality control for clinical islet transplantation: Organ procurement and preservation, the islet processing facility, isolation, and potency tests

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 16, Issue 2, 2009, Pages 131-136

  Yamamoto, Toshiyuki ^a,b   Horiguchi, Akihiko ^a   Ito, Masahiro ^a   Nagata, Hideo ^a   Ichii, Hirohito ^b   Ricordi, Camillo ^b   Miyakawa, Shuichi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical islet transplantation; Islet potency test; Quality control

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; DITHIZONE;

CELL FUNCTION; CELL ISOLATION; CELL VIABILITY; DEGRANULATION; GLYCEMIC CONTROL; GOOD MANUFACTURING PRACTICE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LASER SCANNING CYTOMETRY; NONHUMAN; ORGAN PRESERVATION; PANCREAS ISLET TRANSPLANTATION; QUALITY CONTROL; REVIEW; SAFETY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; ORGAN PRESERVATION; QUALITY CONTROL; TISSUE AND ORGAN PROCUREMENT;

EID: 63649088074     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-009-0064-z     Document Type: Review

References (81)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230.
2. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318.
3. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant. 2005;5:2037.
4. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37:413.
5. Ichii H, Pileggi A, Molano RD, et al. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant. 2005;5:21.
6. Ichii H, Wang X, Messinger S, et al. Improved human islet isolation using nicotinamide. Am J Transplant. 2006;6:2060.
7. Weber DJ, McFarland RD, Irony I. Selected food and drug administration review issues for regulation of allogeneic islets of Langerhans as somatic cell therapy. Transplantation. 2002;74:1816-20.
8. Zoon KC. Dear colleague letter to transplant centers. Allogeneic pancreatic islets for transplantation. Center for Biologics Evaluation and Research (September 2000). http://www.fda.gov/Cber/ltr/ allpan090800.htm. Accessed 3 Dec 2008.
9. O'Gorman D, Kin T, Murdoch T, et al. The standardization of pancreatic donors for islet isolations. Transplantation. 2005;27;80(6):801-6.
10. Zeng Y, Torre MA, Karrison T, Thistlethwaite JR. The correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994;57(6):954.
11. Hanley SC, Paraskevas S, Rosenberg L. Donor and isolation variables predicting human islet isolation success. Transplantation. 2008;15;85(7):950-5.
12. Kin T, Murdoch TB, Shapiro AM, et al. Estimation of pancreas weight from donor variables. Cell Transplant. 2006;15(2):181-5.
13. Brandhorst H, Brandhorst D, Hering BJ, et al. Body mass index of pancreatic donors: A decisive factor for human islet isolation. Exp Clin Endocrinol Diabetes. 1995;103(Suppl 2):23-6.
14. Lakey JR, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation. 1996;61(7):1047.
15. Ponte GM, Pileggi A, Messinger S, et al. Toward maximizing the success rates of human islet isolation: Influence of donor and isolation factors. Cell Transplant. 2007;16(6):595.
16. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) 2007.
17. Brandhorst H, Klitscher D, Hering BJ, et al. Influence of organ procurement on human islet isolation. Horm Metab Res. 1993;25:51-2.
18. Kneteman NM, Lakey JRT, Warnock GL, et al. Pancreas procurement and preservation: Impact on islet recovery and viability. Transplantation. 1994;58(10):1114-9.
19. Ricordi C, editor. Pancreatic islet cell transplantation; 1892-1991. One century of transplantation for diabetes. Austin: RG Landes; 1992.
20. Kneteman NM, Lakey JR, Kizilisik TA, et al. Cadaver pancreas recovery technique. Impact on islet recovery and in vitro function. Transplantation. 1994;58:1114-9.
21. Kneteman NM, Lakey JRT, Warnock GL, et al. Human islet isolation after prolonged cold storage. Diabetes Nutr Metab. 1992;5(Suppl 1):33-7.
22. Federlin K, Bretzel RG, Hering BJ. International islet transplant registry. Newsletter no 4, 1993.
23. Straatsburg IH, Abrahamse SL, Song SW, et al. Evaluation of rat liver apoptotic and necrotic cell death after cold storage using UW, HTK, and Celsior. Transplantation. 2002;27;74(4):458-64.
24. Pokorny H, Rasoul-Rockenschaub S, Langer F, et al. Histidine-tryptophan-ketoglutarate solution for organ preservation in human liver transplantation - a prospective multi-centre observation study. Transpl Int. 2005;17(5):256-60.
25. Leo Roels, Willy Coosemans, Jan Donck, Bart Maes, Jacques Peeters, Johan Vanwalleghem. Inferior outcome of cadaveric kidney preserved for more than 24 hr in Histidine-Tryptophan-Ketoglutarate solution 1. Transplantation. 1998;66(12):1660-4.
26. Payam Salehi, Hansen Michael A, Avila Jose G, et al. Human islet isolation outcomes from pancreata preserved with histidine-tryptophan-ketoglutarate versus University of Wisconsin Solution. Transplantation. 2006;82(7):983-5.
27. Stadlbauer V, Schaffellner S, Iberer F, et al. Occurrence of apoptosis during ischemia in porcine pancreas islet cells. Int J Artif Organs. 2003;26(3):205-10.
28. Baertschiger RM, Berney T, Morel P. Organ preservation in pancreas and islet transplantation. Curr Opin Organ Transplant. 2008;13(1):59-66.
29. Nagata H, Matsumoto S, Okitsu T, et al. Procurement of the human pancreas for pancreatic islet transplantation from marginal cadaver donors. Transplantation. 2006;15;82(3):327-31.
30. Kuroda Y, Kawamura T, Suzuki Y, et al. A new, simple method for cold storage of the pancreas using perfluorochemical. Transplantation. 1988;46(3):457.
31. 2) method of pancreas preservation on human islet isolation, as assessed by the Edmonton isolation protocol. Transplantation. 2002;74(10):1414.
32. Tsujimura T, Kuroda Y, Kin T, et al. Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method. Transplantation. 2002;74(12):1687.
33. Ricordi C, Fraker C, Szust J, et al. Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation. 2003;75(9):1524.
34. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004;4(3):390.
35. Jose Caballero-Corbalan, Torsten Eich, Torbjorn Lundgren, et al. No beneficial effect of two-layer storage compared with UW-storage on human islet isolation and transplantation. Transplantation. 2007;84(7):864-9.
36. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry, sterile drug products produced by aseptic processing - current good manufacturing practice September 2004. http://www.fda.gov/ CbER/gdlns/steraseptic.pdf.
37. US Department of Health and Human Services, Food and Drug Administration. The Code of Federal Regulations. Title 21: Food and drugs, Parts 210 and 211.
38. US Department of Health and Human Services, Food and Drug Administration. The Code of Federal Regulations. Title 21: Food and Drugs, Part 610.
39. US Department of Health and Human Services, Food and Drug Administration. The Code of Federal Regulations. Title 21: Food and Drugs Parts 600 through 680.
40. Ricordi C. Human islet cell transplantation: New perspectives for an old challenge. Diabetes Rev. 1996;4:356-69.
41. Shapiro AM, Ricordi C. Unraveling the secrets of single donor. Success in islet transplantation. Am J Transplant. 2004;4(3):295-8.
42. Lakey JR, Burridge PW, Shapiro AM. Technical aspects of islet preparation and transplantation. Transpl Int. 2003;16(9):613-32.
43. Nakano M, Matsumoto I, Sawada T, et al. Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas. 2004;29(2):104-9.
44. Close NC, Hering BJ, Anand R, et al. (2003) Collaborative islet transplant registry (CITR). In: Cecka M, Terasaki P, editors. Clinical transplants, chapter 11. UCLA.
45. Hering BJ, Wijkstrom M, Eckman P. Islet transplantation: Status, protocols and perspectives, Collaborative islet transplant registry (CITR). In: Gruessner RWG, Sutherland DER, editors. Transplantation of the pancreas, chapter 21. Berlin: Springer; 2004.
46. Okitsu T, Matsumoto S, Iwanaga Y, et al. Kyoto islet isolation method: the optimized one for non-heart-beating donors with highly efficient islet retrieval. Transplant Proc. 2005;37(8):3391-2.
47. Yamamoto T, Ricordi C, Messinger S, et al. Deterioration and variability of highly purified collagenase blends used in clinical islet isolation. Transplantation. 2007;27;84(8):997-1002.
48. Berney T, Molano RD, Cattan P, et al. Endotoxin-mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis. Transplantation. 2001;71:125-32.
49. London NJ, Contractor H, Lake SP, et al. A microfluorometric viability assay for isolated human and rat islets of Langerhans. Diabetes Res. 1989;12(3):141.
50. Latif ZA, Noel J, Alejandro R. A simple method of staining fresh and cultured islets. Transplantation. 1988;45(4):827.
51. Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat. 1990;27(3):185.
52. Bank HL. Assessment of islet cell viability using fluorescent dyes. Diabetologia. 1987;30:812-6.
53. Bank HL. Rapid assessment of islet viability with acridine orange and propidium iodide. In Vitro Cell Dev Biol. 1988;24(4):266-73.
54. Barnett MJ, McGhee-Wilson D, Shapiro AM, et al. Variation in human islet viability based on different membrane integrity stains. Cell Transplant. 2004;13:481-8.
55. Gerling IC, Kotb M, Fraga D, et al. No correlation between in vitro and in vivo function of human islets. Transplant Proc. 1998;30:587-8.
56. Eckhard M, Brandhorst D, Winter D, et al. The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. Transplant Proc. 2004;36:1528-31.
57. McKay DB, Karow AM. Factors to consider in the assessment of viability of cryopreserved islets of Langerhans. Cryobiology. 1983;20:151-60.
58. Lacy PE, Walker BS, Fink CJ. Perifusion of isolated rat islets in vitro: participation of the microtubular system in the biphasic release of insulin. Diabetes. 1972;21:987-8.
59. Socci C, Davalli AM, Vignali A, et al. Evidence of in vivo human islet graft function despite a weak response to in vitro perfusion. Transplant Proc. 1992;24:3056-7.
60. Ricordi C, Scharp DW, Lacy PE. Reversal of diabetes in nude mice after transplantation of fresh and 7-day-cultured (24°C) human pancreatic islets. Transplantation. 1988;45:994-6.
61. London NJ, Thirdborough SM, Swift SM, et al. The diabetic "human reconstituted" severe combined immunodeficient (SCID-hu) mouse: A model for isogeneic, allogeneic, and xenogeneic human islet transplantation. Transplant Proc. 1991;23:749.
62. Lake SP, Chamberlain J, Bassett PD, et al. Successful reversal of diabetes in nude rats by transplantation of isolated adult human islets of Langerhans. Diabetes. 1989;38:244-8.
63. FDA Biological Response Modifier Advisory Committee Summary minutes meeting no. 36, 9-10 October 2003. http://www.fda.gov/ohrms/dockets/ac/ cber03.html. Accessed 3 Dec 2008.
64. Ichii H, Inverardi L, Pileggi A, et al. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant. 2005;5(7):1635.
65. Steinlechner-Maran R, Eberl T, Kunc M, et al. Respiratory defect as an early event in preservation-reoxygenation injury of endothelial cells. Transplantation. 1997;63:136-42.
66. Yang H, Jia XM, Acker JP, et al. Routine assessment of viability in split-thickness skin. J Burn Care Rehabil. 2000;21:99-104.
67. Zhang Y, Ohkohchi N, Oikawa K, et al. Assessment of viability of the liver graft in different cardiac arrest models. Transplant Proc. 2000;32:2345-7.
68. Steurer W, Stadlmann S, Roberts K, et al. Quality assessment of isolated pancreatic rat islets by high-resolution respirometry. Transplant Proc. 1999;31:650.
69. Papas KK, Long RC Jr, Sambanis A, et al. Development of a bioartificial pancreas: I. long-term propagation and basal and induced secretion from entrapped betaTC3 cell cultures. Biotechnol Bioeng. 1999;66:219-30.
70. Sweet IR, Khalil G, Wallen AR, et al. Continuous measurement of oxygen consumption by pancreatic islets. Diabetes Technol Ther. 2002;4:661-72.
71. Papas KK, Wu H, Colton CK. Rapid islet quality assessment prior to transplantation. Cell Transplant. 2001;10:519.
72. Colton CK, Papas KK, Pisania A. Characterization of islet preparations. In: Halberstadt C, Emerich DF, et al. editors. Cell transplantation from laboratory to clinic. New York: Elsevier; 2006.
73. Fraker C, Timmins MR, Guarino RD, et al. The use of the BD oxygen biosensor system to assess isolated human islets of Langerhans: Oxygen consumption as a potential measure of islet potency. Cell Transplant. 2006;15(8-9):745.
74. Papas KK, Colton CK, Nelson RA, et al. Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice. Am J Transplant. 2007;7(3):707.
75. Sweet IR, Gilbert M, Scott S, et al. Glucose-stimulated increment in oxygen consumption rate as a standardized test of human islet quality. Am J Transplant. 2008;8(1):183.
76. Takeuchi H, et al. Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem. 2005;280(11):10444-54.
77. Ohshima S. Apoptosis and necrosis in senescent human fibroblasts. Ann N Y Acad Sci. 2006;1067:228-34.
78. Burnett R, et al. DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA. TTC repeats in Friedreich's ataxia. Proc Natl Acad Sci USA. 2006;103(31):11497-502.
79. Varma H, et al. Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc Natl Acad Sci USA. 2007;104(36):14525-30.
80. Bradbury DA, Simmons TD, Slater KJ, et al. Measurement of the ADP: ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis. J Immunol Methods. 2000;240:79-92.
81. Goto M, Holgersson J, Kumagai-Braesch M, et al. The ADP/ATP ratio: A novel predictive assay for quality assessment of isolated pancreatic islets. Am J Transplant. 2006;6(10):2483-7.